Begin main content

New at CADTH — September 2017

September 19, 2017
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.

Informing Canada’s Response to the Opioid Crisis — An Update from CADTH

September 18, 2017
Delivering on our commitment to provide evidence and resources that support Canada’s response to the opioid crisis continues to be a key priority for CADTH. Over the summer we’ve answered a range of research questions related to the treatment of opioid use disorder and the use of drug and non-drug interventions to manage pain. All of our reports...

Call for Feedback: Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism

September 14, 2017
A draft report on Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism is now available for feedback from all interested stakeholders. Project Call for Feedback Feedback Due By Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism 2017-09-14 2017-09-28 Consultation Document Product Type Submit Stakeholder Feedback Draft Sc...

CADTH Drug Portfolio Information Sessions

September 14, 2017
Event Date: October 3, 2017Location: Beanfield Centre, Room 204 ABC 105 Princes’ Blvd., Toronto, ON The CADTH Drug Portfolio Information Sessions are an opportunity to receive an update on our drug portfolio, including CADTH’s Common Drug Review (CDR), pan-Canadian Oncology Drug Review (pCODR), and Therapeutic Reviews. Updates on other relevant ...

Drugs for Type 2 Diabetes: Second- and Third-Line Therapy Review Update

September 13, 2017
CADTH has completed its Therapeutic Review update of second-line therapies for patients with type 2 diabetes. The following reports are now available on the CADTH website: final science report on second-line therapy (clinical and economic evaluations) final recommendations report on second-line therapy Supporting documents: In Brief — a summary ...